Share Price | Erasca, Inc. Stock Analysis & Recommendation

Q: How big is Erasca, Inc.?

Market Cap: As of Jun 18, Erasca, Inc. has a market capitalization of 386.69 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Erasca, Inc. reported net sales of 0.00 million and a net profit of -157.60 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 423.50 million and total assets of 502.53 million.

Q: What does Erasca, Inc. do?

Overview: Erasca, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -31 Million (Quarterly Results - Mar 2025) Market Cap: USD 386.69 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.75 Return on Equity: -33.82% Price to Book: 0.97Contact Details: Registrar Address: Not available.

Q: Is Erasca, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Erasca, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish, driven primarily by the daily moving averages indicating bullish momentum and the weekly MACD also reflecting a bullish trend. However, the weekly RSI is bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, while the KST shows a bullish weekly signal but is bearish monthly. Despite the bullish indicators, Erasca's performance has been significantly underwhelming compared to the S&P 500, with a year-to-date return of -7.97% versus the S&P 500's 16.30%, and a one-year return of -15.07% compared to 19.89% for the index.

Results Declared: Erasca, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.02 M

Shareholding (Dec 2025)

FII

6.97%

Held by 71 FIIs

DII

46.87%

Held by 41 DIIs

Promoter

31.57%

How big is Erasca, Inc.?

22-Jun-2025

As of Jun 18, Erasca, Inc. has a market capitalization of 386.69 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -157.60 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 423.50 million and total assets of 502.53 million.

View full answer

What does Erasca, Inc. do?

22-Jun-2025

Erasca, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $31 million and a market cap of $386.69 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -33.82%.

View full answer

Is Erasca, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Erasca, Inc. shows a bullish technical trend despite underperforming the S&P 500, with daily moving averages and weekly MACD indicating bullish momentum, while the weekly RSI suggests short-term weakness.

View full answer

Compare Erasca, Inc. with Similar Stocks

KalVista Pharmaceuticals, Inc.Oric Pharmaceuticals, Inc.Arbutus Biopharma Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4,199 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.81

Return on Equity

-33.97%

Price to Book

12.07

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-29 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

327.7%

6 Months

668.06%

1 Year

884.56%

2 Years

582.33%

3 Years

418.37%

4 Years

60.68%

5 Years

0.0%

Erasca, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

3.86%

EBIT to Interest (avg)

-160.96

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.75

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

90.48%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.07

EV to EBIT

-29.11

EV to EBITDA

-29.82

EV to Capital Employed

60.83

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-208.97%

ROE (Latest)

-33.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 36 Schemes (14.58%)

Foreign Institutions

Held by 71 Foreign Institutions (6.97%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 9.63% vs -8.42% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.90",
          "val2": "-34.90",
          "chgp": "8.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.10",
          "val2": "-32.20",
          "chgp": "9.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 22.96% vs -29.28% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-128.30",
          "val2": "-148.60",
          "chgp": "13.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.50",
          "val2": "-27.20",
          "chgp": "65.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-124.50",
          "val2": "-161.60",
          "chgp": "22.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-31.90

-34.90

8.60%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-29.10

-32.20

9.63%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 9.63% vs -8.42% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-128.30

-148.60

13.66%

Interest

0.00

Exceptional Items

-9.50

-27.20

65.07%

Consolidate Net Profit

-124.50

-161.60

22.96%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 22.96% vs -29.28% in Dec 2024

All Annual Results

Company CV

About Erasca, Inc.

Erasca, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available